Literature DB >> 9751120

Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells.

C H Lieu1, C C Liu, T H Yu, K D Chen, Y N Chang, Y K Lai.   

Abstract

The induction of apoptosis by Taxol was investigated in human leukemic U937 cells. Treatment of U937 cells with 20 nM Taxol for 24 h induced apoptosis in 30-40% of cells, which resulted in an 80% growth inhibition 3 days after treatment. Synchronous cells at different cell cycle stages exhibited different sensitivities toward Taxol, and their reversion by certain protein kinase inhibitors was also phase specific. Kinetic studies of cell cycle progress reveal that Taxol accelerates the progression of the cell cycle, which facilitates the process of apoptosis, especially for cells initially in the G1 phase. This acceleration may result from transient activation of p42/ 44 mitogen-activated protein (MAP) kinase, because inhibition of upstream MAP/extracellular signal-regulated kinase kinase (MEK1/2) by PD98059 reversed this effect. However, the delayed S-G2-M-phase progression by PD98059 was insignificant. The results suggest that MAP kinase may not only mediate cell cycle progress but may also participate in the apoptosis pathway for cells originally in S phase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751120

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  8 in total

1.  Hyaluronan suppresses prostate tumor cell proliferation through diminished expression of N-cadherin and aberrant growth factor receptor signaling.

Authors:  Alamelu G Bharadwaj; Nathaniel P Goodrich; Caitlin O McAtee; Katie Haferbier; Gregory G Oakley; James K Wahl; Melanie A Simpson
Journal:  Exp Cell Res       Date:  2011-02-17       Impact factor: 3.905

2.  Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines.

Authors:  H M McDaid; S B Horwitz
Journal:  Mol Pharmacol       Date:  2001-08       Impact factor: 4.436

Review 3.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

4.  Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.

Authors:  X M Liu; L G Wang; W Kreis; D R Budman; L M Adams
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

Review 5.  Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis.

Authors:  Dinesh Vyas; Gieric Laput; Arpitak K Vyas
Journal:  Onco Targets Ther       Date:  2014-06-12       Impact factor: 4.147

6.  LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo.

Authors:  Han-Li Huang; Min-Wu Chao; Chung-Chun Chen; Chun-Chun Cheng; Mei-Chuan Chen; Chao-Feng Lin; Jing-Ping Liou; Che-Ming Teng; Shiow-Lin Pan
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

7.  Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain.

Authors:  Kord M Kober; Man-Cheung Lee; Adam Olshen; Yvette P Conley; Marina Sirota; Michael Keiser; Marilyn J Hammer; Gary Abrams; Mark Schumacher; Jon D Levine; Christine Miaskowski
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

Review 8.  Programmed cell death, redox imbalance, and cancer therapeutics.

Authors:  Xiaofeng Dai; Danjun Wang; Jianying Zhang
Journal:  Apoptosis       Date:  2021-07-08       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.